- 1D
- 1W
- 1M
- 1Y
- 5Y
- YTD
About MannKind
MannKind Corporation is a biopharmaceutical company. The Company is focused on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, such as pulmonary arterial hypertension. The Company's product candidate is Afrezza (insulin human) Inhalation Powder, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and also to improve glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a small and portable inhaler. AFREZZA utilizes its technosphere formulation technology. The technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics.
1.91%
1.54%
Stock Analysis
last close
$3.97
1-mo return
-7.2%
3-mo return
-4.6%
avg daily vol.
2.28M
52-week high
6.25
52-week low
3.12
market cap.
$985M
forward pe
-
annual div.
-
roe
-
ltg forecast
-
dividend yield
-
annual rev.
$81M
inst own.
44.1%
